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ABSTRACT Three-dimensional structures of the transmembrane, seven -helical domains and extracellular loops of , ,
and  opioid receptors, were calculated using the distance geometry algorithm, with hydrogen bonding constraints based on
the previously developed general model of the transmembrane -bundle for rhodopsin-like G-protein coupled receptors
(Biophys. J. 1997. 70:1963). Each calculated opioid receptor structure has an extensive network of interhelical hydrogen
bonds and a ligand-binding crevice that is partially covered by a -hairpin formed by the second extracellular loop. The
binding cavities consist of an inner “conserved region” composed of 18 residues that are identical in , , and  opioid
receptors, and a peripheral “variable region,” composed of 19 residues that are different in , , and  subtypes and are
responsible for the subtype specificity of various ligands. Sixteen -, -, or -selective, conformationally constrained peptide
and nonpeptide opioid agonists and antagonists and affinity labels were fit into the binding pockets of the opioid receptors.
All ligands considered have a similar spatial arrangement in the receptors, with the tyramine moiety of alkaloids or Tyr1 of
opioid peptides interacting with conserved residues in the bottom of the pocket and the tyramine N and OH groups forming
ionic interactions or H-bonds with a conserved aspartate from helix III and a conserved histidine from helix VI, respectively.
The central, conformationally constrained fragments of the opioids (the disulfide-bridged cycles of the peptides and various
ring structures in the nonpeptide ligands) are oriented approximately perpendicular to the tyramine and directed toward the
extracellular surface. The results obtained are qualitatively consistent with ligand affinities, cross-linking studies, and
mutagenesis data.
INTRODUCTION
Three different types of opioid receptors (, , and ),
identified based on their pharmacological properties, have
recently been cloned (see reviews: Reisine, 1995; Dhawan
et al., 1996; Zaki et al., 1996) and assigned to the large
superfamily of rhodopsin-like G protein-coupled receptors
(GPCRs). This superfamily of GPCRs consists of integral
membrane proteins that transduce optical and chemical sig-
nals across the cellular membrane (Watson and Arkinstall,
1994) and share a common 3D structure. The seven-helical
structure of the transmembrane domain has recently been
demonstrated by electron cryomicroscopy (EM) studies of
bovine, frog, and squid rhodopsins with a resolution of 6–9
Å (Schertler et al., 1993; Unger and Schertler, 1995; Unger
et al., 1997; Davies et al., 1996). Many members of the
GPCR family, especially rhodopsin, have been extensively
studied by site-directed mutagenesis and a variety of phys-
icochemical methods. These experimental data and the anal-
ysis of variability and hydrophobicity patterns in amino acid
sequences of GPCRs have made it possible to assign the
transmembrane helices of GPCRs to the peaks in the rho-
dopsin EM maps (Baldwin, 1993), and to construct a num-
ber of different approximate GPCR models (see reviews:
Ballesteros and Weinstein, 1995; Donnelly et al., 1994).
Some of these models have been built from the structure of
the nonhomologous 7--bundle membrane protein, bacte-
riorhodopsin (Henderson et al., 1990), whereas others have
used the low-resolution rhodopsin EM maps and a few
experimentally derived constraints to pack together seven
“ideal” helices with arbitrarily chosen side-chain conform-
ers (for example, Baldwin, 1997; Donnelly et al., 1994;
Herzyk and Hubbard, 1995). The calculation of a more
precise, atomic-level structure requires refinement of the
spatial positions of entire helices, determination of their
precise geometry, as helices are never “ideal” in proteins
(Barlow and Thornton, 1988), and careful attention to side-
chain packing.
To refine the structure of the transmembrane domain, we
have developed and recently described a novel modeling
approach that is based on the presence of numerous polar
residues in the hydrophobic, lipid-embedded -helices of
GPCRs (Pogozheva et al., 1997). It is known that water-
inaccessible polar groups of proteins have a strong tendency
to form H-bonds (McDonald and Thornton, 1994). In trans-
membrane -helices, peptide backbone groups are already
paired, whereas the polar side chains must interact with each
other to form intra- or interhelical H-bonds. The candidate
H-bonding pairs can be identified from the analysis of
sequence alignments as polar residues in intramembrane
segments that appear and disappear simultaneously in var-
ious GPCRs. The corresponding H-bonds can then be used
as constraints for packing the seven -helical fragments by
distance geometry calculations. Moreover, the side-chain
H-bonds from many different GPCRs can be combined to
increase the number of simultaneously applied constraints
and to calculate an “average” 7--bundle structure. The
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computational procedure was organized as an iterative re-
finement with evolving constraints that begins from an
initial model of the -bundle and continues until each
buried polar side chain of each of the 410 GPCRs consid-
ered can participate in at least one hydrogen bond in the
final structure (the root mean square deviation, r.m.s.d.,
between the initial and final structures was 4 Å)
(Pogozheva et al., 1997). This “saturation of hydrogen
bonding potential” (McDonald and Thornton, 1994) crite-
rion was very sensitive to structural mistakes during the
refinement procedure. The transmembrane segments of in-
dividual GPCRs are hydrophobic and contain less than 30%
polar residues, but when 410 different amino acid sequences
are simultaneously considered, all interhelical contacts
within the -bundle are “labeled” by polar side chains
forming intramolecular H-bonds. Displacement of any
-helix from its correct position breaks some H-bonds,
producing unpaired polar side chains within the lipid bilayer
in tens or hundreds of GPCRs.
The “average” atomic structure of the -bundle has been
tested by using it as a template to calculate the transmem-
brane domains of specific GPCRs whose H-bonds and close
packing of nonpolar side chains must be compatible with
the same common structure. The models of 28 different
GPCRs (including vertebrate and invertebrate rhodopsins
and a number of opioid, chemokine, glycoprotein, cationic
amine, melatonin, and purine receptors) were generated by
distance geometry, using H-bonds specific to each receptor,
while using the “average” model to restrain the spatial
positions of the helices. Analysis of the GPCR models
reveals many features that are responsible for structural
stability of the transmembrane -bundle, such as the for-
mation of extensive networks of interhelical H-bonds, aro-
matic and sulfur-aromatic clusters that are spatially orga-
nized as “polarity gradients,” close packing of side chains
throughout the transmembrane domain, and the formation
of interhelical disulfide bonds in many GPCRs (Lomize et
al., 1998). Some other features of the models are related to
biological function and evolution of GPCRs, such as the
formation of a spatially continuous “minicore” of 43 evo-
lutionarily conserved residues, a multitude of correlated
replacements of residues buried within the core, a Na
binding site, and complementarity of receptor binding pock-
ets to many structurally dissimilar, conformationally con-
strained ligands (Lomize et al., 1998).
As has previously been discussed (Pogozheva et al.,
1997; Lomize et al., 1998), the GPCR models obtained are
consistent with a large body of experimental data that were
not used in deriving the models and that therefore can serve
as an independent control. The model of rhodopsin, for
example (1boj and 1bok Protein Data Bank files), is in
agreement with the arrangement of -helices in the low-
resolution 3D EM maps; mapping of water- and lipid-
accessible rhodopsin residues by chemical probes; identifi-
cation of residues surrounding retinal by site-directed
mutagenesis and cross-linking; the orientations of all-trans
and 11-cis retinal relative to the membrane plane and the
distances from the ligand to the intra- and extracellular
surfaces, determined by linear dichroism and fluorescence
quenching; reconstitution studies of opsin with synthetic
retinal analogs; the conformation and environment of the
protonated retinal Schiff base, studied by Raman, Fourier
transform infrared, and 13C solid-state NMR spectroscopies;
cross-linking studies; the compensatory replacements of
Glu113 (III:3) by Asp90 (II:21) or Asp117 (II:7); and many
other data (Pogozheva et al., 1997). (Superscript residue
numbers correspond to the particular receptor sequences.
Numbers in parentheses indicate the helix number (Roman
numerals) and the residue position in 26-residue transmem-
brane segments, identified by Baldwin (1993) (Arabic nu-
merals) and shown in Fig. 1.) The “average” model of the
-bundle is also in agreement with constraints experimen-
tally derived by site-directed mutagenesis for other GPCRs,
such as the proximity of Asp397 (II:28) and Lys583 (VII:3) in
the lutropin/choriogonadotropin hormone receptor (Fernan-
dez and Puett, 1996), Asn87 (II:14) and Asn318 (VII:17) in
the gonadotropin-releasing hormone receptor (Zhou et al.,
1994), Asp120 (II:14) and Asn396 (VII:17) in the 5-HT2A
receptor (Sealfon et al., 1995), Asp125(III:7) and
Lys331(VII:4) in 1B-adrenergic receptors (Porter et al.,
1996), and the formation of an artificial Zn2-binding site
by histidine residues incorporated in positions V:1, V:3,
and VI:27 in mutant NK-1 and  opioid receptors (Elling et
al., 1995; Thirstrup et al., 1996). The models of cationic
amine receptors (Lomize et al., 1998) are consistent with
accessibilities of residues from helices III, V, and VII to
water-soluble probes (Javitch et al., 1995; Fu et al., 1996)
and with a vast sample of site-directed mutagenesis data
demonstrating, for example, the interaction of AspIII:7 with
the protonated amine of ligands (Fraser et al., 1989; Javitch
et al., 1995; Ho et al., 1992; Mansour et al., 1992, 1997;
Porter et al., 1996; Savarese and Fraser, 1992; Strader et al.,
1987, 1988; Wang et al., 1991, 1993), the involvement of
SerV:6 of -adrenoreceptors and SerV:7 of -adrenorecep-
tors in H-bond formation with catechol ligands, the impor-
tance of SerV:10 for ligand binding and activation (Strader
et al., 1989; Wang et al., 1991; Hwa et al., 1997), and the
proximity of the indole rings of Trp109 (III:3) and Trp330
(VII:8) of the 2-adrenoreceptor to the azido group of
iodoazidopindolol, an affinity label for -adrenergic recep-
tors (Wong et al., 1988).
In the present paper, we discuss in detail the 3D structures
of , , and  opioid receptors calculated from the previ-
ously developed “average” model of the transmembrane
domain. This is an especially interesting case for verifica-
tion of the receptor models by ligand docking, because the
three different opioid receptor types have a number of
structurally distinct, conformationally constrained ligands,
from small, rigid alkaloids to larger cyclic peptides, with
well-studied structure-activity relationships (SARs). In ad-
dition, we have included in the models the tentative struc-
tures of the three extracellular loops, which were calculated
by distance geometry. Although the ligand-binding pocket
consists mainly of residues from the transmembrane -bun-
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dle, the extracellular loops of opioid receptors have also
been shown to be important for interactions with many
ligands (Chen et al., 1995; Fukuda et al., 1995; Hjorth et al.,
1995; Meng et al., 1995, 1996; Minami et al., 1996; Onogi
et al., 1995; Pepin et al., 1997; Varga et al., 1996; Valiquette
et al., 1996; Wang et al., 1994, 1995; Xue et al., 1994, 1995;
Zhu et al., 1996a,b), whereas the extracellular N-terminus
can be deleted in m and k receptors (Kong et al., 1994;
Surratt et al., 1994) or exchanged between receptor subtypes
(Meng et al., 1996) without affecting the ligand binding.
METHODS
The modeling described here was done in three stages: 1) distance geom-
etry calculations of transmembrane domains of d, m, and k opioid receptors
from the previously determined “average” transmembrane a-bundle struc-
ture; 2) modeling of the extracellular loops of the opioid receptors; and 3)
incorporation of various opioid ligands into the calculated receptor structures.
Distance geometry calculations of
transmembrane a-bundles for d, m,
and k receptors
The transmembrane 7-a-bundles of d, m, and k opioid receptors were
calculated using their own specific H-bonds, while using the “average”
GPCR model to restrain the spatial positions of the helices, as previously
described for bovine rhodopsin (Pogozheva et al., 1997). The positions of
the helices were restrained by incorporating Cb. . . Cb distances from the
“average” model as the upper limits in calculations with the distance
geometry program DIANA (Gu¨ntert et al., 1991). These Cb. . . Cb limits
were increased by 1 Å (0.5 Å for distances of the more loosely packed helix
I) to allow some relaxation of the specific receptor structures relative to the
“average” model, i.e., small shifts of helices that are necessary to adopt the
replacements of side chains in the “core” of the a-bundle.
FIGURE 1 Sequence alignment of
transmembrane helices (TMH
I–TMH VII) and extracellular loops
(EL-1, EL-2, EL-3) of human d, m,
and k receptors. Asterisks above the
sequences for each helix indicate the
26-residue transmembrane segments,
identified by Baldwin (1993) and
used for identification of GPCR resi-
dues as the number of helix (Roman
numerals):number of residue in the
26-residue fragment (Arabic numer-
als). For example, Asp128 in the d-re-
ceptor sequence is denoted as III:7.
Numbering of the m receptor is that of
the rat receptor for consistency with
mutagenesis data.
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To examine possible H-bonds and to determine conformers of side
chains in opioid receptors, we applied an iterative distance geometry
refinement approach, which we have previously described (Pogozheva et
al., 1997). Each iteration of the refinement included 1) examination of the
structures calculated in the previous iteration for new potential H-bonding
partners (spatially proximate polar groups that did not form H-bonds in the
previous iteration of the model), for correlations in sequence alignments
and for structural flaws (violations of constraints, appearance of hindrances
or holes produced by incorrectly packed side chains, helices that are
multiply curved by contradictory constraints or are loosely packed because
of insufficient constraints); 2) modification of distance and angle con-
straints (H-bonds and conformers of side chains) to increase the number of
simultaneously formed H-bonds, and to correct discovered flaws; and 3)
distance geometry calculations with the modified constraints. The analysis
of calculated structures (step 1) was performed using the program ADJUST
(Pogozheva et al., 1997) and the molecular modeling software QUANTA
(Molecular Simulations). The constraints and the corresponding -bundle
structure evolved simultaneously during the refinement. During the refine-
ment, conformers of most side chains were unequivocally determined.
Final systems of H-bonds are shown in Table 1.
In calculations with DIANA, the -helix geometry was restrained by
backbone H-bonds (upper limits for NHi. . . . OACi4 distances  1.9 Å,
except those broken by Pro residues) and by dihedral angle constraints
(  70° to 50°,   50° to 30°). Because the program requires
a single chain, the loops connecting -helices were approximated by Glyn
fragments, with the number of Gly residues corresponding to the length of
each loop in the -opioid receptor. In the later iterations of the calculations,
glycine residues in the extracellular loops were replaced with the amino
acids corresponding to the opioid receptor sequences (see below). The
standard target function minimization strategy (Gu¨ntert et al., 1991) was
used for calculations. The weighting factors for upper and lower distance
limits and van der Waals and angle constraints initially were 1, 1, 0.6, and
20, respectively, and 1, 1, 2.0, and 5 by the final two iterations. The
HisVI:20 and HisVII:4 side chains were considered to be uncharged, and
all other His, Asp (including AspII:14), Glu, Lys, and Arg side chains were
considered charged.
Modeling the extracellular loops
The extracellular domain of the opioid receptors consists of three loops
(EL-1, EL-2, and EL-3), whose tentative structures are modeled here, and
an N-terminus that was not considered (Fig. 1). It is apparent from the
sequence homology of the loops among the , , and  receptors, that
essentially the same structure can be expected in the different receptor
subtypes. EL-1 and EL-3 are rather short (four or five residues) (Fig. 1),
whereas EL-2 is longer (20 residues in  and  receptors and 23 residues
in the  receptor) and can interact directly with all opioid ligands, because
it partially covers the binding cavity between helices III and VII in the
model of the transmembrane -bundle. Initially, only this longer EL-2 was
added to the transmembrane -bundle for distance geometry calculations.
EL-2 connects transmembrane helices (TMHs) IV and V and is attached to
TMH III by a conserved disulfide bond (Watson and Arkinstall, 1994),
giving this loop a U-like shape (the peptide chain comes from TMH IV
toward TMH III and returns back to TMH V, as shown in Figs. 4 and 5).
Both branches of the U-like EL-2 are too short to form any additional
-helices in the calculated models of the transmembrane domain, and the
geometrical constraints imposed by their attachment to TMH III, IV, and V
force them to adopt extended structures. This extended character of the
peptide chain is also consistent with the general (i, i  2) pattern of
alternate polar and nonpolar side chains around the disulfide bond in amino
acid sequences of opioid receptors and rhodopsins, for example. The
pattern is of the form p-n-p-Cys-p-n-p-Ar, where p, n, and Ar denote polar,
nonpolar, and aromatic residues, respectively. We suggest that the two
extended antiparallel stretches of EL-2 near the conserved disulfide bond
are paired in a -hairpin (residues 195–203 in the , 214–222 in the ,
207–215 in the  receptor), and the two remaining fragments of EL-2,
which connect the -hairpin to helices IV and V, adopt a nonregular
structure. These connections contain Pro, Gly, and polar residues and are
highly variable in families of opioid receptors and other GPCRs. The
characteristic Pro203-Ser204-Pro205-Ser206 sequence in the  opioid recep-
tor, for example, is an excellent breaker of both -helix and -structure.
The nonregular structure of these connections can be also suggested based
on insertions in this region arising in many different GPCRs, such as
insertions of Ser220 and Val205-Asp206 residues in the  receptor (Fig. 1).
The hypothesized -hairpin formation is supported by several observa-
tions. First, the -hairpin provides the formation of many H-bonds between
residues that appear and disappear in a correlated manner in amino acid
sequences of opioid receptors, such as Asp216. . . Thr220, Lys141. . . Asp216,
Ser214. . . Gln314, and His223. . . Glu310 (present only in  receptors),
Glu118. . . Gln201, Glu118. . . Lys122, and Ser204. . . Arg291 (present only in
 receptors), and Lys132. . . Glu209 and Asp216. . . His304 (present only in 
receptors). Two insertions in EL-2 of the  receptor are also correlated:
they provide simultaneous lengthening of both nonregular connections
between the -hairpin and transmembrane helices IV and V, thus allowing
the -hairpin to stay in the same spatial position. Second, the -hairpin can
readily be inserted in the cavity between helices III and VII, without the
appearance of interatomic hindrances, and it forms numerous hydrophobic
contacts and several hydrogen bonds with the transmembrane -bundle.
Third, the structure of the -hairpin itself is stabilized by hydrophobic
contacts of several interacting nonpolar residues (Val196, Leu200, and
Phe202 in the  receptor; Ile215, Leu219, and Phe221 in the  receptor; or
Ile208, Leu212, and Phe214 in the  receptor; see Fig. 5). At the same time,
several polar residues (Gln201 in ; Asp216, Thr218, Thr221 in ; Glu209,
Thr211, Gln213 in  receptors) are arranged on the opposite face of the
-hairpin and form H-bonds with each other and with polar residues from
helix III (Glu/Thr/AspIII:3 and LysIII:1). Fourth, the presence of several
Ser and Thr residues with high -sheet propensities in this region (posi-
tions 214, 218, 220, and 222 in the  opioid receptor, for example) is also
consistent with the hypothesized formation of the -hairpin.
The probable conformation of the -turn in the -hairpin can also be
readily identified. Because the -turn consists of an odd number of residues
(residues 198–200 in , 217–219 in , 210–212 in  receptor), the only
allowed standard type is the type I with a G1 -bulge, i.e., the R	RL
motif (Sibanda and Thornton, 1991). This motif is very common in protein
-hairpins (Sibanda and Thornton, 1991) and has been shown to be
independently stable in aqueous solution (deAlba et al., 1996), because,
unlike the “standard” type I and II -turns, the R	RL turn is consistent
with the direction of twist in -structure (Richardson and Richardson,
1989). In the structure of the  opioid receptor, this turn is further
stabilized by H-bonds formed by the COO group of Asp216 with the
main-chain NH group of Thr218, and between the side chains of Thr218 and
Thr220 (Fig. 5). The consistency of the -hairpin with the entire system of
distance constraints for the -bundle was further verified by distance
geometry calculations for , , and  receptors (the H bonds of the
-hairpin are shown in Table 1).
After incorporation of the -hairpin in the model, the extracellular ends
of TMHs II, III, VI, and VII were extended by one to three residues
(through residues II:28, III:3, VI:3, and VII:2), because these residues
can form fragments of amphiphilic helix with nonpolar side chains facing
the lipid environment. This also provides, simultaneously, many additional
intra- and interhelical H-bonds and hydrophobic contacts between nonpolar
side chains. The remaining extracellular loop fragments (113–117 (EL-1),
190–194 and 204–209 (EL-2), and 290–294 (EL-3) in the  receptor;
130–136 (EL-1), 209–213 and 223–228 (EL-2), and 309–312 (EL-3) in
the  receptor; 123–127 (EL-1), 200–206 and 216–222 (EL-2), and
303–306 (EL-3) in the  receptor) were simply considered as short,
nonregular connections whose tentative structures were defined by distance
geometry calculations based on the appearance of correlated H-bonded
residues in the loops (such as Arg291-Asp290 and Asp288-Arg292-Asp293,
which simultaneously appear only in EL-3 of the  receptor), and con-
straints for dihedral angles  and , which fix them in the allowed areas of
the Ramachandran map (the intervals of the angles were constrained
similarly to that in the REDAC strategy; Gu¨ntert and Wuthrich, 1991). The
final structures of the extracellular loops in all opioid receptors provide
close packing of Trp and Phe residues conserved in EL-1 (positions 114
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TABLE 1 H-bonds of side chains applied as distance constraints for calculation of opioid receptor models
 receptor  receptor  receptor Location
Side chain to side chain
Thr53O	1 Ser106H	 Thr63O	1 Ser116H	 TMHs I–II
Cys60H	 Ser100O	 Cys79H	 Ser119O	 TMHs I–II
Asn67H22 Asp95O1 Asn86H22 Asp114O1 Asn77H22 Asp105O1 TMHs I–II
Asn67O1 Ser312H Asn86O1 Cys330H Asn77O1 Ser324H TMHs I–VII
Thr78O	1 Asn85H21 Thr97O	1 Asn104H21 Thr88O	1 Asn95H21 TMHs I–II
Asn85O1 Tyr318H
 Asn104O1 Tyr336H
 Asn95O1 Tyr330H
 TMHs II–VII
Tyr87O
 Lys166H1 Tyr106O
 Lys185H1 Tyr97O
 Lys176H1 TMHs II–IV
Tyr87H
 Asn169O1 Tyr106H
 Asn188O1 Tyr97H
 Asn179O1 TMHs II–IV
Asn90O1 Tyr130H
 Asn109O1 Tyr149H
 Asn100O1 Tyr140H
 TMHs II–III
Asn90H21 Thr138O	1 Asn109H21 Thr157O	1 Asn100H21 Thr148O	1 TMHs II–III
Asn90O1 Trp173H1 Asn109O1 Trp192H1 Asn100O1 Trp183H1 TMHs II–IV
Asp95O2 Asn131H22 Asp114O2 Asn150H22 Asp105O2 Asn141H22 TMHs II–III
Asp95O2 Asn314O1* Asp114O2 Asn332O1* Asp105O2 Asn326O1* TMHs II–VII
Thr99H	1 Ser312O	 Thr118H	1 Cys330S	 Thr109H	1 Ser324O	 TMHs II–VII
Gln105H22 Asp128O1 Gln124H22 Asp147O1 Gln115H22 Asp138O1 TMHs II–III
Gln105O1 His301H2 Gln124O1 His319H2 TMHs II–VII
Ser106H	 His301N1 Ser125H	 His319N1 TMHs II–VII
Tyr128O
 Thr312H	1 TMHs II–VII
Tyr119O
 Thr306H	1 TMHs II–VII
Glu118O1 Lys122N TMHs III–III
Thr137H	1 Asp216O1 TMHs III–EL-2
Glu118O2 Gln201H22 Asp128O1 Gln213H22 TMHs III–EL-2
Lys141N Asp216O2 Lys132N Glu209O1 TMHs III–EL-2
Asp128O2 Tyr308H
 Asp147O2 Tyr328H
 Asp138O2 Tyr323H
 TMHs II–VII
Asn131O1 Ser311H	 Asn150O1 Ser329H	 Asn141O1 Ser311H	 TMHs III–VII
Thr134O	1 Ser177H	* Thr153O	1 Ser196H	* Thr144O	1 Ser187H	* TMHs III–IV
Ser135H	 Asn314O1 Ser154H	 Asn332O1 Ser145H	 Asn326O1 TMHs III–VII
Thr160H	1 Asn191O1 TMHs III–IV
Asp145O1 Arg146H
12 Asp164O1 Arg165H
12 Asp155O1 Arg156H
12 TMHs III–III
Asp145O2 Lys164H1* Asp164O2 Asn183H22* Asp155O2 Lys174H1* TMHs III–IV
Asp145O2 Lys166H2 Asp164O2 Lys185H2 Asp155O2 Lys176H2 TMHs III–IV
Lys200N Asp204O1 EL-2–EL-2
Arg190N
1 Ser206O	 EL-2–EL-2
Arg202H
12 Asp217O1 EL-2–EL-2
Arg202H
11 Glu218O1 EL-2–EL-2
Gln212H22 Asp216O1 EL-2–EL-2
Gln212O1 Ser222O	 EL-2–EL-2
Asp204O2 Ser220H	 EL-2–EL-2
Asp206O2 His304H1 EL-2–EL-3
Ser214O	 Gln314H22 EL-2–TMH VII
Thr218O	1 Thr220O	1 Ser211O	 Gln213H21 EL-2–EL-2
Ser204O	 Arg291H His223H1 Glu310O1 Asp216O1 His304H1 EL-2–EL-3
His223H1 Gln314O1 EL-2–TMH VII
Tyr208H
 Met186S Tyr227H
 Met205S Trp221H2 Met216S EL-2–TMH IV
Asp210O1 Lys214H1 Glu229O1 Lys233H1 Asp223O1 Lys227H1 TMHs V–V
Asn230O1 Lys233H2 TMHs V–V
Tyr233O
 Arg261H Tyr252O
 Arg280H Tyr246O
 Arg274H TMHs V–VI
Tyr299H
 Ser317O	 TMHs VI–VII
Lys303H2 Ser317O	 TMHs VI–VII
Asp288O2 Arg292H TMHs VI–EL-3
Asp290O2 Arg291N
2 EL-3–EL-3
Arg292N
1 Asp293O2 EL-3–EL-3
Arg292N
2 Asp293O1 EL-3–EL-3
Asn310O1 Asn314H22 Asn328O1 Asn332H22 Asn322O1 Asn326H22 TMHs VI–VII
Side chain to main chain
Tyr56H
 Thr99O Tyr75H
 Thr118O Tyr66H
 Thr109O TMHs I–II
Asn85H22 Lys81O Asn104H22 Lys100O Asn95H22 Lys91O TMHs II–IL1
Tyr87O
 Ala165O* Tyr106O
 Ala184O* Tyr97O
 Ala175O* TMHs II–IV
Lys108N Trp114O TMH II–EL1
H-bonds between residues in corresponding positions in the sequences of , , and  receptors are shown in the same row. Upper distance constraints were
1.9 Å for H. . .O, 2.9 Å for O. . .O and N. . .O, and 2.6 Å for H. . .S bonds. In addition, 15, 18, and 22 H-bonds of threonine and serine side chains with
i  4 backbone carbonyls are also included for , , and  receptors, respectively.
*Distances increased by 0.3 Å.
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and 116 in , 133 and 135 in , and 124 and 126 in  receptors) and the
orientation of most tryptophan, tyrosine, and phenylalanine side chains in
the loops toward the lipid-water interface, where they can interact with
lipid headgroups, as is characteristic for membrane proteins (Deisenhofer
and Michel, 1991; Schultz, 1992; Grigorieff et al., 1996).
Final calculations of the transmembrane domains, including the three
extracellular loops, were made using 64, 69, and 70 side-chain H-bonding
constraints for , , and  receptors, respectively (Table 1); constraints for
dihedral angles of the main chain in the loops and for all side chains of the
transmembrane -bundle; C. . . C distance constraints taken from the
“average” model; and restraints on the geometry of the TMHs, as described
above. The constraints also included backbone H-bonds in the -hairpin of
the EL-2 fragment (residues 195–203 in , 214–222 in , 207–215 in 
receptor) and a conserved disulfide bond connecting this -hairpin to TMH
III. Totals of 877, 896, and 884 angle constraints and 691, 690, and 651
distance constraints were used for calculations of , , and  receptors,
respectively.
The calculations with DIANA yielded well-defined sets of structures for
each (, , and ) opioid receptor (pairwise r.m.s.d. of 212 TMH C atoms
was 0.7 Å for the 10 structures of each receptor with the lowest target
function). The r.m.s.d. between C atoms of TMHs of different (, , and
) receptors was larger (0.9 Å). All backbone angles of the models are
within the allowed regions of the Ramachandran map, and all side chains
have standard 1-4 conformers, as is automatically provided by the
dihedral angle constraints (violations of the individual angle constraints
were10°). A few violations of van der Waals constraints of0.5 Å were
present near Pro residues in -helices; no violations of H-bond distances
greater than 0.6 Å were found. The structures of receptors with the lowest
target function were selected for ligand docking and energy minimization.
Ligand docking
All opioid ligands were inserted manually into the binding pockets, using
the Molecular Modeling module of QUANTA to move the ligands and
control hindrances and receptor-ligand H-bonds. The docking was simpli-
fied by using only rigid or conformationally constrained ligands (Fig. 2 and
Tables 2 and 3) whose structures have been solved by x-ray crystallogra-
phy (Bye, 1976; Klein et al., 1987; Urbanczyk-Lipkowska and Etter, 1987;
Verlinde et al., 1984; Calderon et al., 1997; Doi et al., 1990; Flippen-
Anderson and George, 1994; Griffin et al., 1986; Lomize et al., 1994;
Collins et al., 1996) or NMR spectroscopy (Mosberg and Sobczyk-Kojiro,
1991; Collins et al., 1996). The procedure of manual ligand docking is
similar to assembling a jigsaw puzzle that consists of two semirigid pieces;
however, three circumstances complicated the process. First, because most
of the ligands are not completely rigid, it was necessary to consider several
possible conformers of their flexible elements, such as the N-cyclopropy-
lmethyl group in morphine, the N-phenethyl group in fentanyl, or Tyr1 in
cyclic opioid peptides. Second, in a few cases, described in the Results, it
was necessary to adjust conformers of several receptor side chains in the
binding pocket, which were not unequivocally defined by distance geom-
etry calculations. Third, because the DIANA-generated receptor structures
were not completely identical (although the r.m.s.d of C atoms was low:
0.7 Å), the ligand docking was performed with two or three structures
with the lowest target function.
The receptor-ligand H-bonds and ion pairs served as important attach-
ment points for ligand docking. Two such attachment points are the
carboxyl and imidazole groups of AspIII:7 and HisVI:20, respectively, the
only polar groups situated at the bottom of the binding pocket in all three
calculated opioid receptor models (, , and ). The importance of the
AspIII:7 and HisVI:20 residues for binding opioid ligands has been clearly
demonstrated by mutagenesis (Befort et al., 1996b; Mansour et al., 1997;
Surratt et al., 1994). In the receptor models, these carboxyl and imidazole
groups are arranged in such a way that they can interact simultaneously
with the N and OH groups, respectively, of the Tyr1 or tyramine group
present in most opioid ligands. Importantly, all surrounding side chains in
the bottom of the binding pockets (IleV:4, IleVI:19, CysVII:6, IleVII:7)
can be tightly packed (arranged without hindrances or holes) with the
tyramine fragment of the ligands. It should be mentioned that, even without
consideration of receptor-ligand H-bonds, the largest ligands, such as
norBNI and cyclic peptides, can be inserted in the binding pockets without
hindrances in only one way, because they occupy nearly all available space
within the pockets, and any shift of the ligands would produce significant
overlaps with surrounding receptor atoms. However, for some smaller
ligands, the mode (or modes) of docking can be determined only if key
attachment points of the interacting molecules (H-bonds or ionic interac-
tions) are assumed.
Technically, docking of most ligands was performed in two steps. First,
the tyramine fragment of each ligand was placed in the bottom of the
binding pocket to form H-bonds with AspIII:7 and HisVI:20, while the rest
of the ligand molecule was oriented toward the extracellular surface. Then
the spatial position of the ligand molecule and the conformation of its
flexible elements, which are connected to the tyramine fragment, were
adjusted to exclude all hindrances with receptor atoms and to form addi-
tional H-bonds and hydrophobic contacts in the binding pocket. For ex-
ample, the cyclic peptides considered (Table 3) have rigid, well-defined
structures of their cycles (D-Cys-Phe-D-Pen and D-Pen-Ala-Phe-D-Pen), but
have a considerably more flexible exocyclic Tyr1 residue and side chain of
Phe3 (Deschamps et al., 1996; Lomize et al., 1996). Only structures of the
TABLE 1 Continued
 receptor  receptor  receptor Location
Lys108N Cys198O TMH II–EL-2
Asn127H22 Gly136O TMH II–EL-1
Tyr109H
 Pro294O Tyr128H
 Thr312O Tyr119H
 Thr306O TMH II–EL-3
Thr113H	1 Met111O Thr132H	1 Met130O Thr123H	1 Met121O TMH II–EL-1
Asp128H1 Ser211HN TMH III–EL-2
Asp128H1 Asp128HN TMHs III–III
Arg190H Arg192O Lys209N Arg211O Lys200N Arg192O EL-2–EL-2
Gln212O1 Gly213HN Glu203O1 Asp204HN EL-2–EL-2
Gln212O1 Ser214HN Glu203O1 Val205HN EL-2–EL-2
Asp203O2 Trp221HN EL-2–EL-2
Asp216O2 Ser220HN EL-2–EL-2
Asp216O1 Thr218HN EL-2–EL-2
Ser204H	 Asp290O EL-2–TMH VII
Ser206H	 Arg192O EL-2–EL-2
Trp207H1 Leu286O Trp226H1 Leu305O Tyr219H
 Leu299O EL-2–TMH VII
Asp288O1 Val296HN TMHs VI–VII
Arg291N Ser204O EL-3–EL-2
Asn310H22 Val266O Asn328H22 Val285O Asn322H22 Val279O TMHs VII–VI
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cycles that were determined by x-ray crystallography (Lomize et al., 1994;
Flippen-Andersen et al., 1994; Collins et al., 1996) were examined here.
The structure of the rigid cycle (D-Cys-EPhe-D-Pen) for the -selective
agonist JH-42 was considered to be close to the crystal structure of JOM-13
cycle on the basis of theoretical conformational analysis (Mosberg et al.,
1996). However, during step 2 of the docking procedure, the  angle of
Tyr1, the  angle of the second residue, and the 1 angles of the Phe3(4) and
Tyr1 side chains in these peptides were adjusted to allow the formation of
additional H-bonds and to exclude steric hindrances with the receptor.
Some details of the adjustment for the peptides and other opioid ligands are
described in the Results and Discussion. It should be stressed that the
bound conformations obtained for all ligands were identical or very close
to the crystal structures, both geometrically (Tables 2 and 3) and energet-
ically (the energy differences between crystal and bound conformations
were 0.5–2.0 kcal/mol after energy minimization of the ligands with the
CHARMm force field (Brooks et al., 1983; Momany and Rone, 1992),
using a dielectric constant   10 and the adopted-basis Newton-Raphson
method). Conformational analyses of peptides from the JOM-13 and
[D-Pen2,D-Pen5]enkephalin (DPDPE) series have been discussed else-
where (Lomize et al., 1994, 1996; Mosberg et al., 1994a,b, 1996). The
proposed docking modes were compared with available SAR, cross-link-
ing, and mutagenesis data, as described in detail in the Results and
Discussion for 16 opioid ligands.
After manual docking of the ligands with the Molecular Modeling
module of QUANTA, the steric overlaps between ligand and receptor
atoms did not exceed 0.5 Å. All remaining hindrances were removed
during 35 subsequent iterations of unconstrained minimization of the
complexes with the CHARMm force field (Brooks et al., 1983; Momany
and Rone, 1992), using a dielectric constant   3 and the adopted-basis
Newton-Raphson method. Initial approximations that yielded energies
greater than 2000 kcal/mol after 35 minimization steps were rejected,
because this demonstrated residual hindrances or distorted geometry of
ligands or receptor. The final energies of accepted receptor-ligand com-
plexes ranged from 2803 to 2176 kcal/mol, and the structures of these
complexes were not altered after short-term minimization: the r.m.s.d.
between atoms of ligand and of receptor binding site residues from the
initial and minimized structures were 0.1 Å.
RESULTS AND DISCUSSION
Models of , , and  opioid receptors
The calculated , , and  opioid receptor models are nearly
identical within the transmembrane domain (r.m.s.d. of 212
common C atoms of the TMHs are 0.9 Å); however,
small differences are observed in the extracellular loops
(Fig. 3) because of unequal numbers of residues among the
receptors (Fig. 1). All opioid receptor models have a ligand-
binding cavity that is partially covered by the extracellular
loops (Fig. 4). The loops create an almost continuous sur-
face, with the -hairpin formed by EL-2 in the middle (Fig.
5), surrounded by the smaller, nonregular EL-1 and EL-3.
This region is represented in 3D EM maps of frog and
bovine rhodopsins by a considerable amount of electron
density that does not contain -helices (Unger et al., 1997).
The calculated opioid receptors structures have several
clusters of polar side chains that form extensive networks of
interhelical hydrogen bonds (Fig. 6 and Table 1). Four such
clusters consist of a “core set” of polar residues that are
conserved throughout most GPCRs, augmented by more
variable, peripheral polar residues that are connected to the
central “core” by H-bonds (Pogozheva et al., 1997). The
large, polar cluster I consists of conserved AsnI:18, AspII:
14, SerIII:14, AsnVII:13, SerVII:14, and AsnVII:17 resi-
dues (Asn86, Asp114, Ser154, Asn328, Ser329, and Asn332 in
the  receptor) and is supplemented, in opioid receptors, by
the more variable TyrI:7, ThrII:18, AsnIII:10, Ser/Cys-
FIGURE 2 Structures of nonpeptide opioid ligands.
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VII:15 (Tyr75, Thr118, Asn150, and Cys330 in the  receptor).
Cluster I contains a cavity that can be filled by water or by
a sodium ion coordinated with oxygens of the AspII:14,
AsnIII:10, SerIII:14, SerVII:14, and AsnVI:17 side chains.
Cluster II is formed around the conserved AsnII:9-TrpIV:11
pair by TyrIII:9, ThrIII:13, ThrIII:17, and SerIV:15
(Asn108-Trp192 pair and residues Tyr149, Thr153, Thr157, and
Ser196 in the  receptor). Cluster III consists of the con-
TABLE 2 Torsion angles (degrees) of nonpeptide opiates in the models of receptor-ligand complexes and in published crystal
structures of the ligands*
Compound Receptor Torsion angle Receptor bound conformation
Crystal
structure Reference
BW373U86  C3-N4-C7-C8 48 57 Calderon et al. (1997)*
N4-C7-C8-C9 151 149
C2-N1-C11-C1A 64 67
N1-C11-C1A-C2A 98 99
N1-C11-C1B-C2B 152 165
C3B-C6B-C7B-N1B 116 124
C
SUPERFIT  C1-N1-C15-C16 83 169 Flippen-Anderson and
George (1994)N1-C15-C16-C17 74 175
C2-C4-N2-C12 88 77
N2-C12-C13-C14 57 61
A B C
cis-()-3-Methyl-fentanyl  C1-N1-C15-C16 169 170 86 169 Flippen-Anderson and
George (1994)N1-C15-C16-C17 161 29 78 175
C2-C4-N2-C12 77 96 78 77
N2-C12-C13-C14 83 121 158 61
-FNA  C9-N17-C18-C19 179 176 Griffen et al. (1986)
C5-C6-N6-C21 137 129
N6-C21-C22-C23 179 163
U69,593  C7-C6-N2-C19 77 68 Doi et al. (1990)
C6-C7-N1-C11 110 121
N1-C11-C12-C13 100 94
Compounds and torsion angles are shown in Fig. 2.
*Crystal structure of the closely related 3-F analog.
TABLE 3 Torsion angles of two small cyclic opioid peptides, JOM-13 (Tyr-c[D-Cys-Phe-D-Pen]) and [L-Ala3]DPDPE (Tyr-c[D-Pen-
Ala-Phe-D-Pen]), in the models of  opioid receptor-ligand complexes and in published crystal structures of the peptides
Residue Torsion angle
JOM-13 [L-Ala3]DPDPE
In the model In crystal* In the model In crystal#
Tyr1  137 102 94 120
1 176 171 152 173
D-Cys/Pen2  71 67 87 75
 25 18 12 17
1 60 51 56 60
2 143 141 169 174
3 (SS) 90 89 102 115
Ala3  — — 84 88
 — — 50 42
Phe3(4)  76 84 119 125
 23 15 8 28
1 63 70 46 56
D-Pen4(5)  131 133 96 124
1 77 76 98 86
2 47 50 70 66
*From Lomize et al. (1994). The torsion angles within the 11-membered ring correspond to molecule A, and torsion angles for the exocyclic Tyr residue
and Phe side chain correspond to molecule B (two independent molecules were present in the unit cell).
#From Collins et al. (1996). The torsion angles are for the second of four independent molecules in the crystal unit cell (conformation of the first molecule
in the unit cell differs by 15°, for several angles, from molecules 2, 3, and 4, which are nearly identical).
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served AsnII:4 and TyrVII:21 (Asn104 and Tyr336 in the 
receptor) and the more variable ThrI:28 and AspVII:25
(Thr97 and Asp340 in the  receptor), and cluster IV consists
of the conserved triad AspIII:24-ArgIII:25-TyrIII:25
(Asp164, Arg165, Tyr166 in the  receptor) at the C-terminus
of TMH III, TyrV:22, and ArgVI:3 (Tyr252, Arg280 in the 
receptor) from the ends of helices V and VI and the more
variable TyrII:6, ThrIII:20, SerIII:22, Lys/AsnIV:2, LysIV:4,
AsnIV:7, and Asn IV:10 (Tyr106, Thr160, Ser162, Asn183,
Lys185, Asn188, Asn191 in the  receptor). Clusters I and II
are situated in the middle of the transmembrane domain, and
III and IV are close to the intracellular surface. These
clusters are present in most GPCRs because they contain
many conserved polar residues. The opposite, extracellular
surface of the -bundle, which includes the binding pocket,
forms several smaller “variable” polar clusters that are
specific for different subfamilies of GPCRs. Some of the
subfamily-specific clusters are present in all opioid recep-
tors (GlnII:24-TyrII:28-AspIII:7-TyrVII:11-His/TyrVII:4
and TyrIII:8-Asp/GluV:-1-LysV:3 (Gln124-Tyr128-Asp147-
His310-Tyr316 and Tyr148-Glu229-Lys233 in the  receptor)),
whereas others are found only in  (Thr137-Lys140-Asp216-
Thr218-Thr220, Ser214-Asn230-Gln314-His223-Glu310, and
Tyr299-Lys303-Ser317; Figs. 5 and 6),  (Glu118-Lys122-
Gln201, Ser204-Arg291-Asp290, and Asp288-Arg292-Asp293),
or  (Asp128-Lys132-Glu209-Gln213, Lys200-Arg202-Asp204-
Asp217-Glu218-Ser220, Glu297-Thr302-Ser311-Tyr312, and
Asp206-Asp216-His304; Table 1) subtypes. Extracellular
loops 2 and 3 are connected by a His223. . . Glu310 H-bond
in the  receptor (Asp216. . . His304 and Ser204. . . Arg291 in
 and  receptors, respectively). This H-bond is probably
structurally important, because alkylation of His223 by N-
ethylmaleimide in the  receptor reduces the binding affin-
ity of several opioid ligands (Shahrestanifar et al., 1996).
The positions and tilts of the helices of the transmem-
brane domain of our models differ from all previously
published models of opioid receptors (Alkorta and Loew,
1996; Befort et al., 1996b; Cappelli et al., 1996; Knapp et
al., 1995; Habibi-Nezhad et al., 1996; Metzger et al., 1996)
and other GPCRs that have been deposited in the PDB
(Bernstein et al., 1977), GPCRDB (http://swift.embl-heidel-
berg.de/7tm/) (Oliveira et al., 1993), and CORD (http://
www.opioid.umn.edu) databases. The largest deviations of
our  opioid receptor structure (r.m.s.d. of C atoms in the
range of 4.2–6.5 Å) are observed when compared with the
earliest GPCR models, which were constructed from non-
homologous bacteriorhodopsin structures, or by using 2D
(projection) EM maps of rhodopsin and a few supplemen-
tary experimental constraints. The incorporation of geomet-
ric constraints derived from 3D EM maps of rhodopsins
(Herzyk and Hubbard, 1995) leads to a model with a smaller
(3.9 Å) deviation from our structure. Recently an improved
approximation of the transmembrane domain structure has
been obtained by the direct fit of two kinked and five
straight helices to the 3D EM map of frog rhodopsin (Bald-
win et al., 1997). This model has the lowest r.m.s.d (3.3 Å
for 179 common C-atoms; Fig. 7) when compared with our
structures of the transmembrane domain of the  opioid
receptor or bovine rhodopsin. The 3.3-Å r.m.s.d. between
this model and our model of  opioid receptor originates
from the outward shifts of helices II and V, the shift of the
C-terminus of helix III, and from an almost one-turn shift of
helices V and VI in the direction perpendicular to the
membrane plane in the model of Baldwin et al. (1997). As
a result, and as discussed by the authors themselves, the
model of Baldwin et al. (1997) contradicts some experimen-
tal data, such as the observed formation of a Zn2 binding
cluster in positions V:-1 and VI:27 and in positions V:3 and
VI:27 (Elling et al., 1995; Thirstrup et al., 1996); formation
of H-bonds between residues III:7, V:3, V:6, V:7 and cat-
echolamine ligands (Strader et al., 1987, 1988, 1989; Wess
et al., 1991); interaction of Asp II:14 and Asn VII:17 (Zhou
et al., 1994; Sealfon et al., 1995); and the contact of Gly
III:11 and Phe VI:12 in rhodopsin (Han et al., 1996a,b). All
of these experimental data are simultaneously satisfied in
our models (the models are compared in more detail by
Lomize et al., 1998).
Our previously developed model of rhodopsin considered
the possible rotations of several functionally important,
conserved side chains (GluIII:24, TyrV:22, TrpVI:16, Lys-
VII:11, and TyrVII:21) that can participate in alternative
systems of H-bonds, depending on their possible 1 con-
formers (1  60° or 180°) (Pogozheva et al., 1997).
Analysis of physicochemical data for rhodopsin indicates
that conformational rearrangements of these side chains
could take place during photoactivation of rhodopsin. In
opioid receptors, only gauche (160°) rotamers of the
corresponding TrpVI:16 and TyrVII:11 and the trans (1 
180°) rotamer of AspIII:24 have H-bond partners and/or
lack hindrances with surrounding atoms. Therefore rota-
tions of the side chains of these residues are unlikely. On the
other hand, rotations of the TyrV:22 and TyrVII:21 side
chains are possible, because there is space in the models for
FIGURE 3 Superposition of structures of DIANA-calculated  (bold
line),  (thin line), and  (dashed line) receptors (stereo view). The r.m.s.d.
between 212 C atoms of transmembrane helices of  and ,  and , and
 and  receptors are 0.74, 0.80, and 0.90 Å, respectively.
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both rotamers. Consequently, distance geometry calcula-
tions were performed with two different orientations of the
TyrV:22 and TyrVII:21 side chains. The two sets of struc-
tures obtained were almost identical (r.m.s.d. 0.7 Å).
Hence the precision of our calculations is insufficient to
discriminate the active and inactive conformations of opioid
receptors or to reproduce the shifts of transmembrane heli-
ces that probably accompany activation of GPCRs (Sakmar
and Fahmy, 1995; Farrens et al., 1996; Sheikh et al., 1996;
Shieh et al., 1997). Consequently, we incorporated opioid
agonists and antagonists into the same receptor structures,
calculated with trans rotamers of the TyrV:22 and Tyr-
VII:21 side chains, earlier assigned to the active conforma-
tion of rhodopsin.
Ligand binding
The calculated , , and  receptor structures have deep
binding cavities, situated in the extracellular side of the
transmembrane domain between helices III, IV, V, VI, and
VII. These cavities are partially covered by the extracellular
loops and, especially, by the central -hairpin connecting
TMHs IV and V (Fig. 4). The binding pockets consist of an
inner interhelical “conserved region” that is identical in ,
, and  opioid receptors (GlnII:24, TyrII:28, CysIII:0,
LysIII:1, ValIII:3, AspIII:7, TyrIII:8, MetIII:11, LysV:3,
IleV:4, PheV:7, TrpVI:16, IleVI:19, HisVI:20, CysVII:6,
IleVII:7, TyrVII:11, and a conserved Cys in EL-2) and a
peripheral “variable region” that consists of residues from
the ends of TMHs (positions III:-3, III:4, V:-1, V:0, VI:23,
VI:26, VI:27, VI:31, VII:-1, VII:0, VII:3, VII:4) and from
the extracellular loops (for example, positions 193, 194,
195, 196, 197, 291, 293 in EL-2 and EL-3 of the  receptor).
The majority of residues in the binding pocket have fixed
side-chain orientations. However, several residues can have
different rotamers to accommodate either bound peptides or
alkaloids: AspIII:7 has 1  60° for peptide ligands and
1  180° for alkaloid ligands; HisVI:20 has 2  120° or
40° when interacting with peptide or alkaloid ligands,
respectively; LysV:3 assumes a 3 angle of 180° or 60°,
FIGURE 4 Cartoon representation of trans-
membrane helices and extracellular loops of
-opioid receptors with JOM-13, side view and
top view from the extracellular surface. Helical
fragments are purple, loop fragments are white,
the -turn is orange, the disulfide bridge be-
tween helix III and EL-2 (residues Cys121–
Cys198) is yellow, and JOM-13 is green.
FIGURE 5 Proposed structure of
the -hairpin in EL-2 of the  opioid
receptor with proximal H-bonded po-
lar residues from helices III and VII
and from EL-3 and conserved disul-
fide bond between Cys140(III:0) and
Cys217(EL-2). H-bonds are indicated
by the dashed line.
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and Asp/Glu V:-1 has a 1 angle of 60° or 180° in
complexes with cyclic peptides or complexes with other
opiates, respectively. Furthermore, Tyr312 (VII:3) in the 
opioid receptor has a 1 angle of 60° for peptide and
nonpeptide ligands, except for norbinaltorphimine
(norBNI), which requires 1  180° to provide additional
space for this bulky ligand.
The structures of the binding pockets were tested for
complementarity to 16 rigid or conformationally con-
strained opioid ligands with very different chemical struc-
tures and sizes (Fig. 2). Peptides from the DPDPE and
JOM-13 series were chosen because they have small rigid
cycles and have been extensively studied by x-ray crystal-
lography (Flippen-Andersen et al., 1994; Lomize et al.,
1994; Deschamps et al., 1996), NMR spectroscopy (Mos-
berg et al., 1990; Mosberg and Sobczyk-Kojiro, 1991; Col-
lins et al., 1996), and theoretical methods (Froimowitz,
1990; Wilkes and Schiller, 1991). Larger linear and cyclic
opioid peptides are too flexible to be useful for verification
of receptor models. It was found that crystal structures of all
ligands examined, except DPDPE, fit the pockets, with only
a few flexible torsion angles, in some cases, needing to be
adjusted (Tables 2 and 3). The largest ligands (such as
DPDPE or norBNI) fill almost all of the available space
within the binding cavities and interact with residues from
both “conserved” and “variable ” regions. Smaller alkaloids
(such as morphine and naloxone), on the other hand, interact
predominantly with “conserved” residues in the bottom of
FIGURE 6 H-bond network of the
 opioid receptor (stereo view). Col-
ors of residues depicted: green, Tyr,
Trp; red, Asp, Glu; blue, His, Lys;
yellow, Ser, Thr, Asn, Gln. The re-
ceptor is shown with morphine (pur-
ple) in the binding site. H-bonds are
indicated by the dashed line.
FIGURE 7 Comparison of the -opioid recep-
tor model transmembrane -bundle (blue) and the
EM-based model of Baldwin et al. (Baldwin,
1997) (red) (stereo view).
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the binding cavity, leaving some free space around the
ligand. The results of extensive structure-activity studies of
JOM-13 and DPDPE analogs (Heyl and Mosberg, 1992a,b;
Mosberg et al., 1994a,b; Haaseth et al., 1994) and mutagen-
esis data (Befort et al., 1996a,b; Hjorth et al., 1995; Meng et
al., 1996; Pepin et al., 1997; Surratt et al., 1994; Valiquette
et al., 1996) were used to verify the ligand docking.
The complementarity of rigid opiates and their binding
pockets in the receptor models is evident from two different
criteria. First there is a good geometrical fit; the ligands can
be inserted in the bottom of the binding pocket without
significant hindrances or holes in the area of contact. Sec-
ond, and even more important, there is a spatial comple-
mentarity of groups with similar polarities, such that nearly
all polar groups of the ligands form H-bonds with corre-
sponding polar side chains within the binding pocket,
whereas all ligand nonpolar (aliphatic and aromatic) groups
form stabilizing hydrophobic contacts with nonpolar side
chains of the receptors.
Cyclic peptides
The cyclic pentapeptide DPDPE (Tyr-c[D-Pen-Gly-Phe-D-
Pen]OH) is a standard -selective ligand that is widely used
in studies of opioid receptors (Mosberg et al., 1983). Its
more constrained [D-Cys2, des-Gly3] (JOM-13) and [L-Ala3]
analogs have high  affinities and selectivities, whereas
[D-Ala3]DPDPE is much less potent (Haaseth et al., 1994).
JH-42 is a modified version of JOM-13 with EPhe3 and an
amidated C-terminus, modifications that result in a shift in
binding selectivity from  to  (Ho, 1997). X-ray crystal-
lography shows that DPDPE and [L-Ala3]-DPDPE have
different, unique structures of their tetrapeptide cycles
(Flippen-Anderson et al., 1994; Collins et al., 1996; Des-
champs et al., 1996), whereas JOM-13 is present in the
crystal in two forms (A and B) of its 11-membered ring,
which are similar, except for the configuration of the disul-
fide bridge (S-S torsion angles of 89° and 99°, respec-
tively) (Lomize et al., 1994). In all crystal structures of these
peptides, the Phe3(4) side chains have gauche (160°)
rotamers, but Tyr1 orientations are varied (Deschamps et al.,
1996). The crystal structures of DPDPE and related peptides
are consistent with NMR spectroscopy solution data, indi-
cating conformational rigidity of the cycles (Mosberg et al.,
1990; Mosberg and Sobczyk-Koiro, 1991; Collins et al.,
1996; Lomize et al., 1996). However, theoretical conforma-
tional analyses indicate the possibility of several alternative
low-energy structures of the disulfide-bridged cycle in
DPDPE (Froimowitz, 1990; Wilkes and Schiller, 1991). All
exocyclic elements of these peptides are very flexible in
aqueous solution, i.e., they have undefined angles  and 1
of Tyr1,  of D-Cys/Pen2, and 1 of Phe3(4) (Mosberg et al.,
1990; Mosberg and Sobczyk-Koiro, 1991; Lomize et al.,
1994; Collins et al., 1996).
JOM-13
The cyclic tetrapeptide JOM-13 was positioned in the 
receptor-binding pocket, using crystal structures A and B of
its 11-membered cycle, but with adjusted torsion angles for
the exocyclic Tyr1 residue and 1 of Phe3. First, Tyr1 was
positioned in the bottom of the pocket to simultaneously
form H-bonds between its N and OH groups with O1 of
Asp128 (III:7) and N2 of His278 (VI:20), respectively (the
corresponding N. . . O distances are 2.7 and 3.1 Å, respec-
tively, in the final model of the receptor-ligand complex).
This can be done only in the trans (1  180°) orientation
of the Tyr1 side chain. Next, the gauche orientation of
Phe3 (1  60°) was chosen based on SAR for JOM-13
analogs (Mosberg et al., 1994b, 1996). Then the spatial
position of the disulfide-bridged 11-membered ring relative
to the fixed Tyr1 was adjusted by rotating torsion angles 
of Tyr1 and  of D-Cys2. The ring position was adjusted
simply to remove all significant hindrances between the ring
and surrounding receptor residues. The  receptor-bound
conformation thus determined is very close to crystal struc-
ture B of JOM-13, except for the configuration of the
disulfide bridge (S-S torsion angle  90°), which corre-
sponds to crystal structure A (Table 3).
The bound conformation of JOM-13 geometrically fits
the binding pocket of the  receptor and forms a number of
complex-stabilizing H-bonds and hydrophobic contacts
with surrounding receptor residues (Fig. 8). The binding
pocket can be arbitrary divided into subsites that are com-
plementary to smaller structural elements of JOM-13, i.e.,
its Tyr1 residue, D-Cys2-D-Pen4 disulfide bridge, Phe3 side
chain, and C-terminal COO group. The positively charged
nitrogen of Tyr1 is located in a relatively polar binding
subsite formed by several H-bonded residues from helices
II, III, and VII (Gln105(II:24), Asp128(III:7), Tyr129(III:8),
and His301(VII:4)). The aromatic ring of Tyr1 occupies the
bottom of the cavity between Tyr129(III:8), Met132(III:11),
Ile215(V:4), Trp274(VI:16), His278(VI:20), Val281(VI:23),
Leu300(VII:3), Cys303(VII:6), and Ile304(VII:7). There are a
few small empty spaces around Tyr1 in the pocket, which
FIGURE 8 JOM-13 (bold line) inside the binding pocket of the -opioid
receptor (stereo view). Conserved (thin solid line) and variable (thin
dashed line) residues of the binding pocket (within 4.5 Å of the ligand) are
also shown.
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can accommodate methyl groups in the 2	 and 6	 positions
of Tyr1 and the extra ring of trans-Hpp1 (trans-3-(4	-hy-
droxy)-phenylproline), consistent with the high affinities
observed for the corresponding JOM-13 analogs (Mosberg
et al., 1994a). On the other hand, the CH-atom of Tyr1 is
in close contact with Tyr129(III:8), and an additional C-
methyl group incorporated here would experience steric
hindrance with the aromatic ring of Tyr129(III:8), consistent
with the decreased affinities of MeTyr1, Hai1 (6-hydroxy-
2-aminoindan-2-carboxylic acid), and Hat1 (6-hydroxy-2-
aminotetralin-2-carboxylic acid) analogs of JOM-13 (Mos-
berg et al., 1994a). The Tyr129(III:8) side chain also forms
an O
1⁄4HN H-bond with the first peptide group of JOM-13,
thus explaining the low affinity of [NMe-D-Cys2]JOM-13
(Heyl, 1991). Replacements of Tyr1 by D-Tyr1 and Tic1
residues, which have entirely different orientations of the
tyrosine ring within the pocket, produce numerous overlaps
with surrounding receptor atoms, which correlates with the
observed low binding affinities of D-Tyr1 and Tic1 analogs
of JOM-13 (unpublished observations).
The disulfide bonded D-Cys2-D-Pen4 pair of JOM-13 in-
teracts primarily with the side chains of Thr211(V:0),
Thr285(VI:27), Ile289(VI:31), and Leu300(VII:3). -Methyl-
ation of Cys2 is expected to decrease binding, because the
Me group would overlap with Leu300(VII:3) in the model.
This is in agreement with the reduced binding affinity found
for [Me-D-Cys2] JOM-13 (Heyl, 1991). The presence of
empty spaces near the C-hydrogens of D-Cys2 in the model
is consistent with the comparable affinity observed upon
replacement of D-Cys2 by D-Pen2 in analogs of JOM-13
(Mosberg et al., 1988).
The Phe3 side chain of JOM-13 (conformer with 1 
60°) occupies the bottom of a rather large nonpolar cavity
that is extended toward the extracellular side of the -bun-
dle and is covered by a -hairpin formed by EL-2 (the
aromatic ring of Phe3 is located below the conserved
Cys121(III:0)-Cys198(EL-2) disulfide bond and interacts
with Gln105(II:24), Leu125(III:4), Val297(VII:1), and
His301(VII:4); see Fig. 11). The presence of significant
empty space in this cavity might allow a reorientation of the
Phe3 side chain from 1  60° to 1  180°. In this case,
the aromatic ring of Phe3 would occupy an alternate posi-
tion, above the disulfide bond, and would interact primarily
with residues from EL-2 (Val197, Cys198) and the extracel-
lular terminus of TMH III (Glu118(III:-3), Cys121(III:0),
Lys122(III:1), Leu125(III:4)). However, in the model, this
would require a shift of the tripeptide ring system of JOM-
13, which creates steric hindrances between Tyr1 of the
peptide and Tyr129(III:8) of the receptor. Therefore, the
preferred orientation of Phe in the  receptor is gauche
(1  60°), in agreement with the high affinities of
[zPhe3] and [(2R, 3S)MePhe3] analogs of JOM-13 (Mos-
berg et al., 1994b, 1996), in which the 1 angles of residue
3 are fixed in this orientation. The reduced  binding affinity
observed for [EPhe3]JOM-13, in which 1 of Phe3 is fixed
at 180° (Mosberg et al., 1996), is also consistent with the
model. The size of the cavity in which the Phe3 side chain
is situated can be increased even further if the Leu125 (III:4)
side chain assumes an alternative orientation, with a differ-
ent 1 angle. In this case, the cavity can accommodate even
larger side chains, such as those of Nal3 (naphthylalanine)
or Trp3 in the same 1  60° orientation, consistent with
the high affinity of the corresponding analogs of JOM-13
(Heyl and Mosberg, 1992a).
The C-terminal COO group of JOM-13 forms a H-bond
with the  amine of Lys214(V:3) (1  60°, 2  180°,
1  180°, 1  180°), buried inside the -bundle. The
ionic interaction between these oppositely charged groups is
lacking for carboxamide terminal peptide ligands, such as
the carboxamide analog of JOM-13, which displays a 10-
fold reduction in  binding affinity (Mosberg et al., 1988).
The  bound conformation of JOM-13 determined here is
in agreement with SAR studies of JOM-13 analogs with
modified first and third residues (Mosberg et al., 1994a,b).
These studies indicate that the Tyr1 and Phe3 side chains
have trans and gauche orientations, respectively; however,
the conformation of the peptide group between Tyr1 and
D-Cys2 is less defined. Two alternative conformers of JOM-
13, with a  angle of D-Cys2 160° or 70° were found to
be energetically plausible and consistent with SAR data. Of
these, the   160° conformer was proposed to be the
binding conformation, because it provided a better super-
position of all pharmacophoric elements (Tyr1 residue and
Phe3 side chain) in different analogs of JOM-13 (Mosberg
et al., 1994a,b). However, it is clear from the ligand-recep-
tor docking examined here that only the alternate   70°
conformer can fit the binding pocket. Indeed, the receptor
models show that a precise superposition of all pharma-
cophoric elements is not required and that, even in similar
cyclic peptides, the functionally important phenylalanine
aromatic ring may change orientation and location slightly,
as further discussed below.
JH-42
Comparison of  and  receptor models explains some
differences in  versus  selectivity among peptides from
the JOM-13 series. For example, modification of the Phe3
residue and amidation of the C-terminus of the -selective
JOM-13 produces the -selective peptide JH-42 (Tyr-c[D-
Cys-EPhe-D-Pen]NH2). The parent peptide, JOM-13, fits
the binding pocket of the  receptor, interacting with
Leu300(VII:3). However, in the  receptor model, the side
chain of the Trp318(VII:3) residue, which appears in place of
Leu300(VII:3) of the  receptor, is partially overlapped with
the tripeptide cycle of JOM-13 or its analog, JH-42. This
causes a shift of the entire peptide within the binding pocket
(Fig. 9), which, in turn, induces reorientation of the Phe3
side chain from the gauche to the trans 1 conformer to
avoid steric overlap with Cys140(III:0). As a result, the
aromatic ring of Phe3 is relocated in the  receptor to the
alternative spatial position above the conserved Cys140(III:
0)-Cys217(EL-2) disulfide bond, between Thr137(III:-3),
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Cys140(III:0), Lys141(III:1), Ile144(III:4), Gln212(EL-2),
Asp216(EL-2), and Cys217(EL-2). Therefore, fixing the aro-
matic ring in this trans orientation via the EPhe3 modifi-
cation in JH-42 improves affinity to the  receptor.
The peptide C-terminus also interacts differently with 
and  receptors. In the  receptor model, the C-terminal
COO group of JOM-13 forms an ion pair with the -amino
group of Lys214 (V:3), which is partially buried in the
binding pocket. In the  receptor model, the corresponding
Lys233 (V:3) forms an ion pair with Glu229 (V:1), which
replaces the Asp found in the  receptor. Because of the
shifted position of the peptide ligand in the  versus the 
receptor, noted above, the negatively charged peptide C-
terminus makes contact with the COO group of Glu V:1
in the  receptor as well as with the -amino group of Lys
V:3. Therefore, amidation of the C-terminus in JH-42,
which removes the unfavorable electrostatic repulsion with
the glutamic acid, improves  binding, whereas incorpora-
tion of a negatively charged COO in JOM-13 improves 
binding.
[L-Ala3]DPDPE and DPDPE
X-ray crystallography studies (Deschamps et al., 1996) have
led to the interesting observation that the crystal structures
of two high-affinity analogs of DPDPE, the des-Gly3 ana-
log, JOM-13, and [L-Ala3]DPDPE, are very similar to each
other, but differ from the crystal structure of DPDPE itself
(Lomize et al., 1996). Remarkably, all torsion angles of
[L-Ala3]DPDPE, even including the flexible, exocyclic Tyr1
residue and 1 of Phe, are close to those in crystal structure
B of JOM-13, except for the angles of the disulfide bonds,
which are nearly the same as in structure A of JOM-13
(Table 3). As a result, the crystal structure of
[L-Ala3]DPDPE can be incorporated in the binding pocket
of the  opioid receptor exactly as is JOM-13, with almost
identical positions of Tyr1 residues, disulfide bonds, and
C-terminal COO groups in both related peptides. Because
of insertion of the Gly residue, the Phe4 aromatic ring in
[L-Ala3]DPDPE is shifted by 3 Å (compared to that in
JOM-13) toward the extracellular surface in the binding
cavity.
In contrast to its [L-Ala3] analog, the crystal structure of
DPDPE itself could not be incorporated in the receptor
model, even with conformational adjustments of Tyr1 and
Phe3 residues. Incorporation of this crystal structure in the 
receptor model either breaks H-bonds of Tyr1 with
His278(VI:20), or produces strong steric hindrances between
the 14-member ring of DPDPE and the receptor (this hap-
pens, in part, because the Tyr1 and Phe4 side chains are too
widely separated in the crystal structure of DPDPE). How-
ever, the alternative, “L-Ala3-like” conformer of DPDPE
(Lomize et al., 1996) fits the binding pocket well. Thus the
 bound conformation of DPDPE is close to the crystal
structures of its two high-affinity analogs, JOM-13 and
[L-Ala3]DPDPE, which are more conformationally con-
strained than DPDPE itself.
Morphinans and benzomorphans
The positions of the largest rigid alkaloid ligands within the
binding cavity are unequivocally defined by steric restric-
tions. For example, there is only one way in which the bulky
bimorphinan norBNI (Portoghese et al., 1987) can be placed
in the cavity of the  receptor without the appearance of
significant hindrances with surrounding receptor atoms.
This docking mode simultaneously provides ionic interac-
tions between the positively charged 17-N atom of norBNI
and the COO group of Asp138(III:7) (N. . . Od1 distance of
5.8 Å) and between the symmetrical 17	-N of norBNI and
Glu297 (VI:26) of the  receptor (N. . . Oe1 distance of 3.1
Å), consistent with SAR studies of norBNI analogs (Por-
toghese et al., 1994) and mutagenesis experiments (Hjorth
et al., 1995). At the same time, 17-N can form a H-bond
with Tyr138(III:8) or Tyr312(VII:3), the 14-OH group of
norBNI forms a H-bond with Tyr139 (III:8), and the ligand’s
14	-OH group H-bonds with Glu297 (VI:26) of the  receptor.
In contrast, some small alkaloid ligands, such as mor-
phine, can be arranged in several sterically allowed alternate
positions in the pocket, all of which provide contact be-
tween the ligand N and AspIII:7 and which permit the
formation of H-bonds between ligand and receptor polar
groups. To satisfy SAR data, which suggest a similar func-
tional importance and environment of specific ligand groups
FIGURE 9 Superposition of  and  receptor
models with inserted JOM-13 (dark purple) and
JH-42 (dark green), respectively (stereo view).
Receptor residues that are within 4.5 Å of the
ligands and are different in  and  receptors are
shown in light purple and light green, respec-
tively. Lys214(233) is also shown, because it as-
sumes different side-chain conformers in the 
and  receptors. Numbering in the figure corre-
sponds to the  receptor.
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common to a structural class, the general position of both
small and large ligands of the same structural type (such as
norBNI and morphine) were assumed to be similar, with
only a small (2 Å) vertical adjustment within the cavity
allowed. Two slightly different positions of morphine in the
binding cavity are demonstrated in Fig. 10. The first, “up-
per” position of morphine is closer to the extracellular
surface; the tyramine moiety of morphine is in a position
similar to that of Tyr1 of opioid peptides, except that the N
group of the tyramine is slightly farther from the side-chain
carboxylate group of Asp147(III:7) (the N. . . O1 distance
for morphine is 4.0 Å, compared with 2.7 Å for JOM-13).
The 3-OH group of the morphine tyramine moiety forms a
H-bond with N1 of His297 (VI:20) of the  receptor. In the
second, alternate, “lower” position, N of morphine is lo-
cated 1.5 Å deeper in the pocket, and the entire ligand
molecule is shifted 2 Å toward TMH V. In this position,
the side chain of Asp147 (III:7) in the  receptor can change
orientation (1 changes from 60° to 180°) and form a
H-bond with the N of morphine; the NH hydrogen in ring
D is oriented axially and is directed toward O1 of the
Asp147(III:7) (distance of 3 Å). Ring A of morphine in both
positions interacts with Ile234(V:4), Trp293(VI:16),
Ile296(VI:19), Val300(VI:23), and Cys321(VII:6) side chains,
and the 3-OH group of ring A is at a distance of 3.5 Å from
N1 of His297(VI:20) (Fig. 8). Ring D interacts with the side
chains of the conserved Tyr148(III:8), Met151(III:11), and
Ile322 (VII:7) residues. Ring C contacts the side chains of
the conserved Lys233 (V:3) (1  60°, 2  180°, 3 
60°, 4 180°) and Tyr148(III:8), and with the  subtype-
specific Asn230(V:0) and Trp318(VII:3).
Bulky substituents of morphine derivatives usually im-
pose additional steric constraints and substantially decrease
the degrees of freedom of the ligand inside the cavity. For
most alkaloid antagonists with N-allyl and N-cyclopropyl-
methyl substituents (naloxone, naltrindole (NTI), norBNI,
-funaltrexamine (-FNA)), the “lower” spatial position is
probably preferred because the ligand N-substituents, in
their energetically preferred equatorial positions, can be
geometrically arranged, without steric hindrances, in a nar-
row hydrophobic “cleft” between the side chains of
AspIII:7, MetIII:11, TrpVI:16, IleVII:7, GlyVII:10, and
TyrVII:11, whereas the polar groups of the alkaloids form
several H-bonds with surrounding polar side chains, includ-
ing NH (ligand). . . COO AspIII:7 and 14-OH (li-
gand). . . O
 TyrIII:8. Indeed, the importance of the TyrIII:8
side chain and hydroxyl group for interaction with 14-OH
groups of naloxone and NTI has been demonstrated recently
by mutagenesis (Befort et al., 1996b).
Some morphinans with bulky substituents, such as the
14-acetamido group of 14-(bromoacetamido)morphine
(BAM), the N-phenethyl group of phenethylmorphine, or
the N-oxy-cyclopropylmethyl group of bremazocine, can be
geometrically arranged only in the “upper” position, be-
cause any other locations produce steric overlaps of the
substituents with receptor side chains in the binding cavity.
Moreover, the OH group that is attached to the N-cyclopro-
pylmethyl substituent in bremazocine further stabilizes the
ligand in the “upper” position in all opioid receptors by
forming H-bonds with Gln124II:24 and AspIII:7 side chains.
In these ligands, the C9-N17-C18-C19 dihedral angle, which
defines the spatial position of the N-substituents (Fig. 2), is
changed from 180° (as in naloxone, NTI, and norBNI in
the “lower” position) to 60° to geometrically fit the
binding pocket. This positions the N-substituents closer to
the extracellular side between the Leu/MetII:21, GlnIII:24,
Ile/LeuIII:4, AspIII:7, IleVII:7, and TyrVII:11 side chains.
It is possible that functional antagonism in morphinan
alkaloids originates from a combination of features, such as
the presence of specific N-substituents, the “lower” location
of the ligand, and the rotation of the receptor AspIII:7 side
chain. It is noteworthy that all related alkaloids situated in
the “upper” position, such as bremazocine and phenethyl-
morphine, are agonists (Ro¨mer et al., 1980; Casy and Parf-
itt, 1986). Moreover, all agonists described below
(BW373U86, aryacetamides, and fentanyl analogs) and the
cyclic peptides discussed previously are situated in the
“upper” position that is associated with the 1  60°
conformer of AspIII:7. Some possible suggestions about the
mechanism of opioid antagonism can be made by analogy
with rhodopsin. Physicochemical studies of rhodopsin indi-
cate that a rigid body movement of TMHs III and VI
probably takes place during photoactivation (Farrens et al.,
1996; Sheikh et al., 1996; Shieh et al., 1997). This move-
ment may disrupt the ionic interaction between Glu113
(III:3) and Lys296 (VII:11), which is usually treated as the
key event in the activation of rhodopsin (Fahmy et al.,
1995), because replacement of Glu113 (III:3) or Lys296 (VII:
11) produces constitutively active mutants (Robinson et al.,
1992). In all opioid and cationic amine receptors, this
Glu. . . Lys pair is replaced by the conserved pair of
Asp(III:7) and Tyr(VII:11), connected by a H-bond. Tyr308
(VII:11) in the  opioid receptor corresponds to Lys296
(VII:11) of rhodopsin, whereas Asp128 (III:7) is situated in
TMH III, one turn away from the position of Glu113 (III:3)
in rhodopsin. It has been shown that Asp117(III:7) can also
serve as a counterion of the retinal protonated Schiff base in
rhodopsin (Zhukovsky et al., 1992). It can be proposed that
the ionic interaction of AspIII:7 with the protonated amine
of opioid agonists can trigger the movement of TMH III and
FIGURE 10 Two positions (solid and dashed lines) of ()-morphine in
the binding pocket of the -opioid receptor (stereo view). The ligand is
denoted by the bold line, and receptor residues within 4.5 Å of the ligand
by the thin line.
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the rotation of the AspIII:7 side chain. N-Cyclopropyl-
methyl and N-allyl substituents, characteristic of alkaloid
opioid antagonists (Casy and Parfitt, 1986), are in close
contact with TMH III in our models and may prevent its
shift during activation, thus leading to functional antago-
nism. It is interesting to note that after superposition of
opioid receptor and rhodopsin models, the N-cyclopropyl-
methyl group of NTI and norBNI and the N-allyl group of
naloxone spatially overlap with a fragment of the polyene
chain (between the 9-methyl group and 11–12-cis double
bond) of the natural “antagonist” of rhodopsin, 11-cis-reti-
nal, which is more deeply embedded between the helices,
than its “agonist” analog, the all-trans isomer of retinal
(PDB files 1bok and 1 boj).
Comparison of the ligands docked in the models of the ,
, and  opioid receptors also explains subtype selectivity
for the morphinan alklaloids considered here. For example,
the preferred binding of morphinans to the  receptor can be
explained by the presence of an additional H-bond between
Asn230(V:0) and the 6-OH group of morphine (see Fig. 10)
or the 6-keto group of naloxone (Asn230 (V:0) is replaced by
Thr and Leu in  and  receptors, respectively). The inter-
action of the Trp318 (VII:3) (1  60°) aromatic ring with
ring C can further contribute to the higher affinity of these
ligands for the  subtype (this Trp318(VII:3) residue is
replaced by Leu and Tyr in  and  receptors, respectively).
On the other hand, the indole ring of the -selective antag-
onist NTI (Portoghese et al., 1987) (Fig. 2) interacts favor-
ably with Thr211 (V:0), Lys214(V:3), Ile289(VI:31),
Val296(VII:1), Val297(VII:0), and Leu300 (VII:3) in the 
receptor model, but has substantial steric hindrances with
the corresponding, more bulky Asn230(V:0), Gln314(VII:
1), and Trp318(VII:3) in the  receptor model, or
Leu224(V:0), Leu309(VII:0), and Tyr312 (VII:3) in the 
receptor model. This agrees with the observation that mu-
tations of Val297(VII:0) and Leu300 (VII:3) decrease binding
of NTI to  receptor (Valiquette et al., 1996; Meng et al.,
1996).
Piperazine derivatives (BW 373U86)
The recently discovered -selective agonist BW373U86
(Fig. 2), in the conformation corresponding to the crystal
structure of its 3-F analog (Calderon et al., 1997; Table 2),
properly fits the binding pocket of the  opioid receptor
(Fig. 11). The 3-hydroxybenzyl moiety of BW373U86 spa-
tially corresponds to the A ring of morphine, but has a
different orientation of its phenyl ring. The 3-hydroxy group
of BW373U86 is pointed toward His278 (VI:20) (O. . . N2
distance is 2.6 Å), one nitrogen of the piperazine moiety is
close to the Tyr129 (III:8) O
H group (N. . . O distance is 3.3
Å), and the other, positively charged nitrogen interacts
electrostatically with Asp128 (III:7) (1  60°) (N. . . O1
distance is 4.0 Å). Like the N-allyl substituent of naloxone,
the N-allyl group of BW373U86 forms favorable hydropho-
bic contacts with Asp128 (III:7), Met132(III:11), Ile304(VII:
7), and Tyr308(VII:11). However, in BW373U86 the N-allyl
group is shifted toward TMH II by 1.5 Å compared with
its position in morphinan antagonists. As a result, this group
is situated between TMH III and VII, rather than between
TMH III and VI as in antagonist naloxone, and does not
interact with Trp274(VI:16), which accounts for the agonist
activity of BW373U86. The Asp128 (III:7) side chain has the
same orientation as in peptides. The diethylbenzamide frag-
ment of BW373U86 interacts with residues at the extracel-
lular ends of helices III, V, VI, and VII (Leu125(III:4),
Thr211(V:0), Lys214(V:3), Thr285(VI:27), Ile289(VI:31),
Val296(VII:1), Val297(VII:0), and Leu300(VII:3)) and with
Ala195 from EL-2 of the  receptor. This could explain the
decreased affinity of BW373U86 analogs for  receptor
mutants with replacements for residues Ile289(VI:31),
Val296(VII:1), Val297(VII:0), and Leu300 (VII:3) (Vali-
quette et al., 1996; Pepin et al., 1997; Meng et al., 1996).
Fentanyl analogs
The -selective agonists cis-()-3-methylfentanyl and
lofentanyl (Fig. 2) were inserted into the binding pocket of
the  receptor model using, primarily, the crystal structure
of cis ()-3-methylfentanyl (Flippen-Anderson and
George, 1994). In the crystal structure, the piperidine ring of
fentanyl is in a chair conformation, the 4-phenylpropana-
mide substituents are in equatorial positions, and the N-
phenethyl moiety is in an extended conformation (see Table
2 for dihedral angles). The docking of three different ori-
entations of the N-phenethyl fragment, one extended (A)
and two bent (B and C) (Table 2), was examined. The
accommodation of structure A in the  receptor model (Fig.
12) requires the rotation of the Gln124(II:24) side chain,
which exposes its amide bond to the lipid phase. This
energetically unfavorable polarity mismatch seems un-
likely. In conformation B the phenyl ring of the phenethyl
fragment is closely packed between TMH II, III, and VII. In
this orientation substituents on the phenyl ring cannot be
accommodated, because of a lack of space between residues
FIGURE 11 The -selective agonist BW373U86 (bold line) inside the
binding pocket of the -opioid receptor (stereo view). Conserved (thin solid
line) and variable (thin dashed line) residues of the binding pocket (within
4.5 Å of the ligand) are also shown.
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Asp147 (III:7), Ile322 (VII:7), and Tyr316 (VII:11). Because
such phenyl ring-substituted fentanyl analogs do indeed
bind with high affinity (Casy and Parfitt, 1986; Zhu et al.,
1996a), this orientation of the ligand is also unlikely. Thus
conformation C, with the phenyl ring oriented toward the
extracellular surface, is the most reasonable choice for the
binding conformation of fentanyl analogs. In the C con-
former, the phenyl ring of 3-methylfentanyl occupies the
same spatial position as Phe3 in the cyclic peptide JOM-13.
In this conformation the 3-methylfentanyl is placed in the
bottom of the binding cavity, and the positively charged
piperidine nitrogen is close to O1 of Asp147(III:7) (N. . .
O1 distance is 3.7 Å; Fig. 8). The piperidine ring contacts
Asp147(III:7), Tyr148(III:8), Trp318(VII:3), and Ile322(VII:7),
and the carbonyl oxygen of the 3-methylfentanyl amide
forms a H-bond with Lys233 (V:3) and Tyr148(III:8). The
aromatic ring of the 4-phenylpropanamide moiety interacts
with Ile234(V:4), Trp283(VI:16), Ile296(VI:19), His297(VI:
20), Val300(VI:23), Cys321(VII:6), and Ile322(VII:7). The
3-methyl group of fentanyl analogs forms additional hydro-
phobic contact with Tyr148(III:8) and Ile322(VII:7) from
helix VII, and the COOCH3 group in position 4 of the
piperidine ring of lofentanyl forms a H-bond with Lys233
(V:3) and Asn230 (V:0), present only in the  receptor.
Fentanyl and its analogs can be readily positioned in the
binding pocket of the  receptor, but the lost favorable
interaction with Trp318 (VII:3) (replaced in the  receptor by
Leu300(VII:3)) decreases the binding affinity. In the  re-
ceptor, Tyr313(VII:4) replaces His(VII:4) of  and  recep-
tors, and has steric hindrances with fentanyl derivatives,
consistent with the reduced binding affinity for this receptor
subtype.
Arylacetamides
The majority of highly -selective agonists are derived from
the prototype U50,488 (Szmuszkovicz and Von Voight-
lander, 1982), which is structurally unrelated to morphine
congeners. As an example of this arylacetamide series, the
second-generation analog U69,593 (Lahti et al., 1985) (Fig.
2) was inserted in the  receptor model (Fig. 13). The
crystal structure of the ligand (Doi et al., 1990) provides a
good fit to the model. The pyrrolidine ring of U69,593 is
located between Asp138(III:7), Tyr139(III:8), and Ile316(VII:
7), and the central ring system is oriented toward the extra-
cellular side, interacting with residues from helices II, III,
and VII (Glu115(II:24), Ile135(III:4), Leu309(VII:0), and
Tyr313(VII:4)) and with the conserved Cys131(III:0)-
Cys210(EL-2) disulfide. The benzacetamide group occupies
the same region of space as the tyramine moiety of alka-
loids, but is oriented in a perpendicular direction. It forms
contacts with residues Tyr139(III:8), Leu224(V:0), Ile228(V:
4), Ile294(VI:23), Tyr312(VII:3), and Ile316(VII:7). The car-
bonyl forms a H-bond with Tyr139 (III:8) and is close to
Lys227 (V:3) (N. . . O distance 3.7 Å). The interactions of
this ligand with residues from many helices is consistent
with mutagenesis data that reveal the importance of all
helices for the binding of U69,593 to the  receptor
(Metzger and Ferguson, 1995). The selectivity of U69,593
for the  receptor subtype appears to result from the pres-
ence of the  receptor-specific residues in helices V–VII
(Leu224(V:0), Ile294(VI:23), Leu309(VII:0), Tyr312(VII:3),
and Tyr313(VII:4)), which modify the shape of the binding
pocket.
Affinity labels
The , , and  receptor models were tested further by
examining irreversible ligands that covalently attach to spe-
cific residues in the binding pockets. The -affinity label
-FNA (Fig. 2) was positioned in the  receptor model, like
to the parent morphine in the “lower” position (Fig. 10),
with the fumarate double bond within 3.0 Å of the -amine
of Lys233 (V:3), allowing covalent attachment. Recently,
chimera studies and site-directed mutagenesis have demon-
strated that Lys233 (V:3) is indeed the site of -specific
irreversible binding of -FNA (Chen et al., 1996). -FNA
irreversibly modifies  receptors but binds reversibly to 
and, with lower affinity, to  receptors (Takemori and
Portoghese, 1985). This results from the existence of dif-
ferent conformers of the LysV:3 side chain in , , and 
receptors. In  receptors Lys233 (V:3) forms a H-bond with
Glu229 (V:1) and adopts a conformer (1  60°, 2 
180°, 3  60°, 4  180°) that positions the -amine
FIGURE 12 Two conformations of cis-()-3-methylfentanyl (B, dashed
line; C, solid line) in the -opioid receptor (stereo view). The ligand is
denoted by the bold line, and receptor residues within 4.5 Å of the ligand
by the thin line.
FIGURE 13 The -selective alkaloid agonist U69,593 (bold) in the
binding pocket of the -opioid receptor (stereo view). Conserved (thin
solid line) and variable (thin dashed line) residues of the binding pocket
within 4.5 Å of the ligand are also shown.
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group of the lysine near the fumarate double bond of the
affinity label. However, the Glu V:1 residue is replaced
by Asp in  and  receptors. In the models of receptor–-
FNA complexes, Lys V:3 can still form a H-bond with the
shorter side chain of the corresponding Asp V:1, but this
requires a different conformer of the side chain: 3 of Lys
V:3 must be changed from60° to 180°. In this conformer,
the distance between the -amine of LysV:3 and the fuma-
rate double bond of the ligand is increased (
5.0 Å) such
that covalent attachment does not occur. In addition, the
-branched Thr211(V:0) in the  receptor sterically inter-
feres with -FNA, substantially decreasing the ligand
affinity.
The -selective ligand SUPERFIT (cis-()-3-methylfen-
tanyl isothiocyanate) (Fig. 2) was positioned in the  model
as in the parent fentanyl in conformation C (Fig. 12). In this
arrangement, the p-isothiocyanate of SUPERFIT can form a
covalent bond with the -amino group of Lys122 (III:1)
(160°, 260°, 360°), which is located near
by (distance between N of Lys122(III:1) and S of the ligand
is 2.7 or 4.7 Å for 4 of Lys122(III:1)  180° or 4  60°,
respectively). This is in agreement with receptor chimera
studies which indicate that SUPERFIT is covalently at-
tached to a residue in the region 76–134 of the  receptor
(Zhu et al., 1996a). Although LysIII:1 is a common residue
for , , and  receptor subtypes, SUPERFIT selectively
modifies  receptors. As in the case of selective labeling of
 receptors by -FNA discussed above, the  selectivity of
SUPERFIT results from different environments and differ-
ent rotamers of LysIII:1 in different receptor subtypes (see
H-bonds with LysIII:1 in different receptors, shown in
Table 1).
BAM (Fig. 2) is a sulfhydryl alkylating reagent that
specifically labels -opioid receptors after reduction of an
unidentified disulfide bond close to the binding site (Bid-
lack et al., 1989). To avoid steric hindrances between the
acetamido group of BAM and the Tyr148(III:8) side, the
ligand was positioned in the  receptor model in the same
fashion as its congener phenethylmorphine (see the “upper”
position of morphine, represented by the dashed line in Fig.
10). In the receptor bound complex, the 14-bromoacet-
amido group of BAM is close to Cys140(III:0) (distance
between Br and C of Cys140(III:0) is 6.1 Å). Our model
thus predicts that it is the SH group of Cys140 (III:0) that
becomes available for modification by BAM after reduction
of the Cys140(III:0)-Cys217(EL-2) disulfide bond by
dithiothreitol.
The -selective labeling reagent 2-(3,4-dichlorophenyl)-
N-methyl-N-[1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)
ethyl] acetamide (DIPPA) (Fig. 2) was inserted into the
binding pocket of the  receptor model in a conformation
similar to its x-ray structure (Chang et al., 1994) and similar
to the binding mode of U69,593. The 3-isothiocyanate
group of DIPPA is near Lys132 (III:1) (distance between N
of Lys132 (III:1) and S of DIPPA is 2.8 Å), and is likely to
modify its -amino group.
Mutagenesis data
The opioid receptor models are generally consistent with
published SAR data for their ligands, covalent labeling, and
mutagenesis data. The site-directed mutagenesis data can be
divided into two groups. The first group includes mutagen-
esis of residues that are near the binding pocket of the
calculated models. Replacement of many residues in the
“conserved” region of the binding pocket, which are in-
volved in the models in the formation of H-bonds with polar
groups of the ligands, affects the binding of numerous
ligands from different structural classes (Befort et al.,
1996a,b; Chakrabarti et al., 1997; Surratt et al., 1994; Man-
sour et al., 1997). In particular, in all opioid receptor mod-
els, AspIII:7 forms the ionic pair or hydrogen bond with N
of all opioid ligands. This correlates with the deleterious
effect of the AspIII:73Asn substitution on receptor activa-
tion and the binding of ligands, especially agonists (mor-
phine, bremazocine, and peptides), to  and  receptors
(Surratt et al., 1994; Befort et al., 1996a). Furthermore,
TyrIII:8, TrpVI:16, and HisVI:20, whose mutations have
been demonstrated to affect ligand binding (Befort et al.,
1996b; Surratt et al., 1994; Mansour et al., 1997), interact
directly with different ligands in the models: TyrIII:8 forms
a H-bond with the first peptide group of JOM-13 and other
cyclic peptides and with the 14-OH group of morphinans;
HisVI:20 forms a H-bond with the hydroxyl group of Tyr1
of peptides and the tyramine moiety of alkaloids; TrpVI:16
interacts with the aromatic ring of Tyr1 or ring A of alka-
loids. The effect of Tyr(VII:11) substitution on ligand bind-
ing (Mansour et al., 1997) can be explained by its partici-
pation in the H-bond network with Asp(III:7), the key
residue for electrostatic interaction with N of all opioid
ligands. Mutations in the “variable” region of the pocket,
especially of residues from the extracellular ends of helices
VI and VII in  receptors (Val281(VI:23), Trp284(VI:26),
Ile289(VI:31), Arg291(EL-3), Arg292(EL-3), Val296(VII:-1),
Val297(VII:0), and Leu300 (VII:3)), which contact the disul-
fide ring of -selective cyclic peptides, the diethylbenz-
amide fragment of BW373U86, and the indole ring of
naltrindole, corroborate the importance of this region for
selective binding of -ligands (Valiquette et al, 1996; Pepin
et al., 1997; Meng et al., 1996). The formation of H-bonds
between 14	-N and 3	-OH of norBNI and Glu297 (VI:26)
in the  receptor model correlate with the important role of
Glu297 (VI:26) for selective binding of norBNI to the 
receptor, suggested from mutagenesis results (Hjorth et al.,
1995). Certainly the effect of the same replacement on
binding of different ligands may vary significantly, because
the energy of the receptor-ligand interaction depends on the
structure of the ligand and on its precise position relative to
the mutated residue. As described above, ligands of differ-
ent structure and size interact with different sets of residues
and have slightly different positions in the binding pocket,
although they occupy the same cavity between TMHs III,
IV, V, V, and VII.
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The second set of data includes mutagenesis of residues
that are remote from the binding pocket in our models.
Replacements of many residues, located between helices II
and III and between helices VI and VII in this set, have
negligible effects (Fukuda et al., 1995; Minami et al., 1996;
Valiquette et al., 1996), but others (AspII:14, Lys/AsnII:27,
TprIV:11, SerIV:15, PheV:11) can strongly affect the bind-
ing of opioid ligands (Surratt et al., 1994; Kong et al., 1994;
Chakrabarti et al., 1997; Claude et al., 1996; Befort et al.,
1996b; Fukuda et al., 1995; Minami et al., 1996). In our
model, all residues indirectly affecting ligand binding are
tightly packed at the helix-helix interfaces, and most of
them (AspII:14, Lys/AsnII:27, TrpIV:11, SerIV:15) also
form interhelical H-bonds (see Table 1). The replacement of
such tightly packed residues by residues of different volume
and/or H-bonding capability is expected to produce shifts of
entire helices, as is always observed in similar mutagenesis
studies of buried, core residues in -helical proteins
(Daopin et al., 1991; Eriksson et al., 1992; Baldwin et al.,
1993, 1996), or during the natural evolution of -helical
proteins (Lesk and Chothia, 1980; Chothia and Lesk,
1985a,b). The shifts of the -helices can, in turn, affect
ligand binding. Thus, for example, the deleterious effect on
binding observed when the bulky Phe222 (V:11) and Trp173
(IV:11) residues are replaced by Ala in the  receptor
(Befort et al., 1996b) can be expected. Similarly, replace-
ment of Lys108 (II:27) (Fukuda et al., 1995; Minami et al.,
1996), which forms H-bonds between its -NH3
 group and
two main-chain CAO groups from EL-1 and EL-2, can
induce conformational changes in the loops, indirectly af-
fecting binding of ligands, especially large ones, such as
DPDPE and other peptide ligands, which strongly interact
with EL-2 in the models.
Some of the remote mutations can be expected to affect
the stabilities of the inactive and active receptor states
differently, and therefore have different effects on the bind-
ing of agonists and antagonists. For example, replacement
of Ser177 (IV:15) in  opioid receptor by Leu produces a
mutant that can be activated by antagonists (Claude et al.,
1996). In our model, this replacement is expected to shift
TMH III relative to TMH IV, because there is no space
between the H-bonded Thr134 (III:13) and Ser177 (IV:15)
available for the more bulky Leu side chain. The shift of
helix III has previously been suggested as an activation step,
based on mutagenesis and physicochemical studies of rho-
dopsin (Sakmar and Fahmy, 1995; Shieh et al., 1997;
Sheikh et al., 1996; Farrens et al., 1996); therefore the helix
movement induced by Ser177(IV:15)3Leu mutation may
facilitate the activation process. Such a shift of the helices
can be expected by analogy with all other -helical proteins
studied, where it has been shown that incorporation of a
single, more bulky residue in the tightly packed protein core
can never be relieved by rotating side chains or distorting
rigid -helix geometry, but requires helix movements
(Daopin et al., 1991; Baldwin et al., 1993, 1996).
Another interesting example is the mutation of the con-
served aspartate in helix II (AspII:143Asn, Ala) in  and 
receptors, which decreases binding of agonists but not an-
tagonists and affects activation of G-proteins (Kong et al.,
1993; Surrat et al., 1994; Chakrabarti et al., 1997). This
Asp95(II:14) residue has been implicated in the binding of
Na to the  opioid receptors, because the presence of
sodium ions affects agonist (but not antagonist) binding in
the native but not in the D95N mutant receptor (Kong et al.,
1993). In our  opioid receptor model, Asp95(II:14) partic-
ipates in a H-bond network with the polar residues
Asn131(III:10), Ser135(III:14), Ser311(VII:14), and Asn314
(VII:17) (Table 1), which, together with a water molecule,
can coordinate the sodium ion (Lomize et al., 1998). The
binding of Na is expected to distort the H-bond network,
as do the D95N, A mutations. The presence or absence of
these H-bonds may be associated with the active and inac-
tive states of the receptors, respectively, which would ex-
plain the lack of effect of the D95N mutation and Na
binding affect on antagonist binding.
From the above discussion it can be seen that all three
opioid receptor models are in qualitative agreement with
published mutagenesis data. A more detailed, quantitative
comparison of the opioid receptor models with mutagenesis
results is not feasible, because this requires the prediction of
structural consequences of single-site mutations, which
sometimes produce significant conformational changes in
proteins (Louie and Brayer, 1989; Houset et al., 1991; Sauer
et al., 1992), and the calculation of free energies of receptor-
ligand interactions, which in itself is a very challenging
problem (Kollman, 1993).
CONCLUSIONS
The , , and  opioid receptor structures described here
represent specific examples of our recently developed gen-
eral model of the 7--helical transmembrane domain, cal-
culated by iterative distance geometry refinement to provide
saturation of “H-bonding potential” simultaneously in 410
different GPCRs. The structures of the extracellular loops
proposed here are more tentative and require experimental
verification; however, there are several arguments in sup-
port of the calculated models. First of all, the model is
consistent with general principles of protein structure: it
provides formation of a single continuous “minicore” of 43
evolutionarily conserved GPCR residues, merges side
chains with similar polarities into clusters, and allows nu-
merous correlated replacements of spatially close side
chains, which is necessary to maintain close packing within
the transmembrane domain (Lomize et al., 1998). The sec-
ond indicator of the validity of the general model stems
from the excellent agreement of the bovine rhodopsin
model, which we have previously described, with a vast
sample of physicochemical data available for this prototyp-
ical GPCR (Pogozheva et al., 1997). The third verification
of the model, described in the present work, comes from
ligand docking. The opioid receptor models were calculated
here solely from H-bonding constraints, using no informa-
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tion about their ligands. Nevertheless, the models have
binding pockets that match crystal structures of different
rigid opiates, including alkaloids, arylacetamides, pirerazine
and piperidine analogs, and small cyclic peptides, as de-
scribed in the “ligand binding” section above. Moreover, the
calculated models are in agreement with affinity labeling
studies of opioid receptors. In particular, the models dem-
onstrate that, in the  receptor model, -FNA can modify
Lys233 (V:3) and BAM can alkylate Cys140 (III:0) after
reduction of the conserved S-S bond between Cys140 (III:0)
and Cys217 (EL-2) by dithiothreitol, SUPERFIT can be
attached to Lys122 (III:1) in the  receptor model, and
DIPPA can covalently modify Lys132 (III:1) in the  recep-
tor model.
Like rhodopsin, the structures of opioid receptors have
only one binding cavity in which all agonists and antago-
nists can be arranged in a similar although not identical way.
The common “message” (Portoghese et al., 1990) tyramine
moiety of alkaloids, or Tyr1 of cyclic peptides lies at the
bottom of the binding cavity and interacts primarily with
residues that are common to all opioid receptors. The N
and OH groups of the tyramine, or Tyr1, form H-bonds with
AspIII:7 and HisVI:20 receptor residues, respectively, even
though the exact spatial positions of these ligand groups
vary by 0.5–4.3 Å, depending on the ligand. The chemically
different “address” fragments of the ligands (such as the
indole group of NTI, or the oligopeptide cycle of DPDPE)
are oriented perpendicular to the tyramine fragment, toward
the extracellular surface of the transmembrane domain, and
interact with many residues that differ among the , , and
 receptors and are situated along the “walls” of the binding
cavity, or in the extracellular loops. Thus the spatial distri-
bution of conserved and subtype-specific residues in the model
match the “message” and “address” fragments of opiates.
There are several features that distinguish alkaloid ago-
nists and antagonists: the antagonists are shifted slightly
deeper in the binding pocket; they have an N-substituent of
characteristic size inserted between TMH III and TMH VI;
and antagonist binding probably requires rotation of the
AspIII:7 side chain, which interacts with the N group of
both agonists and antagonists. The incorporation of a bulky
N-terminal group between TMH III and TMH VI may
sterically prevent the shift of these helices relative to each
other during activation, thus leading to functional antago-
nism. The rigid body movement of TMHs III and VI during
activation is suggested by recent physicochemical studies
and by site-directed mutagenesis of bovine rhodopsin (Far-
rens et al., 1996; Sheikh et al., 1996; Shieh et al., 1997).
The structures of , , and  receptors with JOM-13,
()-morphine, and U69,593, respectively, have been depos-
ited in the PDB database. Structures of other receptor-ligand
complexes described here are available from the authors
upon request.
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